Inhibitors of Mammalian Aquaporin Water Channels

1Aquaporins (AQPs) are transmembrane proteins that facilitate the bidirectional transport of water across cell membranes; water flows through AQP pores following an osmotic gradient to support water homeostasis. A subset of the AQP family, the aquaglyceroporins, also allows the transport of glycerol and other small neutral solutes such as urea and ammonia. These include AQP3, AQP7, AQP9, and AQP10. Currently, there are 13 known mammalian AQPs, each with a structure comprising six membrane-spanning helices (Table 1). The amino- and carboxy-termini of APQs are both intracellular. Two opposing, shorter helices do not span the entire membrane (Figure 1), but form the pore itself. These half helices contain the family’s signature triplet amino acid NPA (Asn-Pro-Ala) motif, as seen in Figure 1a. The residues in this motif orient water molecules to prevent protons from entering the channel, as well as acting as the hydrogen bond donors and acceptors that facilitate the passage of water molecules. The narrowest segment of the AQP channel is within the transmembrane region of the pore. For AQP1, it is 2.8 Å in diameter, which is similar to the size of a single water molecule. This feature means water molecules pass through AQPs in single file. A high resolution (0.88Å) X-ray crystal structure of a yeast AQP, Aqy1, revealed that the selectivity filter within the pore contains four positions for water molecules and that it is not possible for these positions to be occupied simultaneously. Instead they travel in a pairwise fashion, filling two of these positions at a time.

2AQPs form homotetramers within the plasma membrane. Each homotetramer consists of four water channels (Figure 1b). Each water channel is functionally independent. It has been shown that channel pore size can sometimes be variable. When the residues responsible for the widening and narrowing of the channel entrance were in an ‘open’ state, molecular dynamics simulations suggested that the channel entrance was wider in monomeric than tetrameric AQP5, although it is not clear how this might affect water permeability. For AQP4, functional and mutagenesis studies suggested that non-tetrameric AQPs have the same water permeability as those found in tetramers. Although the reason AQPs form tetramers is not fully understood, it has been shown that non-tetrameric forms of AQP4 do not undergo hypotonicity-induced intracellular trafficking.

3A controversial topic in AQP biology, related to their homotetrameric nature, has been their conduction of ions and whether this takes place. AQP tetramers contain a potential fifth central pore as shown in Figure 1b, reminiscent of cation channels such as Kir 2.1. The use of forskolin has been reported to induce cationic permeability in AQP1, however, follow-up experiments by different groups failed to replicate this. Direct binding of cGMP to AQP1 expressed in Xenopus oocytes has been shown to cause an ionic current after cGMP binding to a predicted site found in the AQP1 carboxyl tail. The central pore of AQP1 was also found to be gas permeable using molecular dynamics simulations. However, conduction of O2 and CO2 through AQP1 may only be physiologically relevant in membranes of low gas permeability where there are high concentrations of AQPs. Recently, a review of evidence for the gas permeability of AQPs suggested that that it may be functionally important in some cells, but not in others. Less controversially, AQP6 is permeable to nitrate and chloride ions, and AQP8 is permeable to ammonia. In a high resolution X-ray crystal structure of human AQP5, however, a lipid molecule co-crystallized with the protein, occluding the fifth central pore, suggesting another possible role.

4AQP channels facilitate the movement of water and small uncharged solutes across membranes down a concentration gradient. As such, they are implicated in a myriad of diseases and AQP modulators are thought to be promising therapeutic targets for new drug development. In some cases, compounds that modify the transcription and translation of AQPs may also be beneficial such as modifying AQP7 expression as a treatment for obesity. Most of the information currently known about AQPs pertains to AQPs 1, 2, 3, and 4, which are the focus of this review. Table 1 shows the currently-known structural and functional features of AQP family members. AQP4 appears to have the highest known water permeability of the AQPs and its role as the major AQP within the central nervous system (CNS) supports this, as tight control is required to ensure optimal conditions for CNS function. The lowest permeabilities are seen in AQP0 and AQP6. The main function of AQP0 as the major intrinsic protein (MIP) in the eye lens (where it has a structural and adhesive function) means that it does not require a high water permeability. AQP6 is an intracellular AQP, but its main function is not yet known.

5AQP1 was first identified in red blood cells and is linked to pathologies such as cancer, the inability to concentrate urine, and altered pain sensation. Expression of AQP1 in some tumor types is correlated with increased angiogenesis, invasion, metastasis, and growth. Aggressive melanomas were shown to have higher expression of AQP1. Silencing of the AQP1 gene in a mouse melanoma xenograft model, reduced angiogenesis and metastasis. In addition to this, it was found that matrix metalloproteinase (MMP) 2 was downregulated upon AQP1 knockdown although it was not determined which of AQP1 or MMP2 was important in mediating this effect. AQP1 is also found in the endothelial cells of the lungs and epithelial cells of bile ducts as well as the kidney tubules and in the epithelia of the proximal convoluted tubule and the loop of Henle. AQP1-deficient humans are unable to concentrate their urine beyond 450 mOsm compared to the more normal 1000 mOsm and above. They are also prone to fluid accumulation in the lungs. Modulating AQP1 may therefore lead to treatments that can aid conditions of excess fluid such as heart failure and cirrhosis. Another role of AQP1 is pain perception; its deletion can cause a reduction of pain from inflammation or cold providing a possible basis for analgesia. There is also evidence to show AQP1 in the choroid plexus where cerebrospinal fluid is produced.

6AQP2 is found in the kidneys, specifically within the cells of the collecting duct. Its regulation is one of the best-studied examples of hormone-mediated AQP translocation; following vasopressin (anti-diuretic hormone) release, AQP2-containing vesicles translocate to the plasma membrane facilitating water reabsorption. Vasopressin binds to V2 receptors of the principal cells in the renal collecting ducts, activating cAMP and protein kinase (PK) A, which phosphorylates Ser-256 and causes the exocytosis of AQP2-containing vesicles. Central diabetes insipidus is the lack of vasopressin and its key symptoms are polyuria with an inability to concentrate urine. Nephrogenic diabetes insipidus (NDI) is usually caused by a problem with the vasopressin receptor on collecting duct cells and is often linked to the AQP2 gene expression. There are also cases of inherited NDI which can be caused by the same vasopressin receptor mutations but also mutations in the AQP2 gene; 19 such mutations have been identified. Acquired diabetes insipidus is seen in cases such as long term lithium therapy where AQP2 subcellular localization can become dysregulated resulting in reduced surface localization and therefore loss of AQP2 function. When vasopressin is secreted inappropriately, high levels of water retention and hyponatremia occur. This is also seen in conditions such as congestive heart failure, where there is increased water retention due to an upregulation of vasopressin, and consequently AQP2 expression and translocation to the plasma membrane. The exact mechanism by which AQP2 is recycled in the principal collecting duct cells is not yet known, however clathrin-coated pits are thought to have a role in this process.

7AQP3 is an aquaglyceroporin that allows the transport of glycerol in addition to water. It is found in the epithelia of renal collecting ducts, urinary tract, digestive tract, and respiratory tract. It is also found in the skin and aids skin hydration. The overexpression of AQP3 is linked to skin malignancies such as melanomas. AQP3 knock-out (KO) mice have been shown to be resistant to tumor formation in skin cancer models through reduced glycerol transport, resulting in lower ATP formation and reduced cell proliferation. AQP3 has also been shown to transport hydrogen peroxide and this function aids NF-κB signaling. AQP3 KO mice had reduced H2O2 levels, impaired NF-κB activation and a reduced induction of psoriasis. In addition to this, AQP3 has roles within the normal function of bacterial phagocytosis by macrophages and the trafficking of T cells.

8AQP4 is the main water channel expressed in the CNS and is found at highest concentration in astrocyte end-feet, which together with blood vessels form the blood–brain barrier (BBB). AQP4 expression is increased in cerebral edema and ischemia. This has been shown to be correlated with the release of inflammatory cytokines. AQP4 is also thought to aid the migration of astrocytes when neuronal injury occurs and glial scars form. AQP4 has been shown to have a link with seizures where the regulation of cell volume by water flow can reduce susceptibility to seizures. For the potassium channel, Kir 4.1, to be active, water flow through AQP4 is required. During trauma or ischemia to the brain, there is a state of hypoxia which is then followed by a failure in Na+, K+, and Cl− pumps in the plasma membrane, causing dysregulation of osmolality. This results in an increased intracranial pressure (ICP) and cerebral edema due to water flow, primarily into astrocytes during the cytotoxic phase of cerebral edema. Limited therapeutic options are currently available to control cerebral edema. They are restricted to the administration of hyperosmotic solutions (such as mannitol, glycerol, and sodium chloride), hypothermia, or ultimately a surgical intervention to remove part of the skull to alleviate the uncontrolled rise in ICP. AQP4 inhibition may be beneficial in cytotoxic edema as AQP4 KO mice were protected from cytotoxic edema.. Vasogenic edema occurs due the movement of water and plasma proteins across a leaky BBB. In models of vasogenic edema, however, AQP4 KO resulted in worse outcomes, due to an inability to remove excess water from brain tissue. Any inhibition of AQP4 function, therefore needs to be acute.

9Neuromyelitis optica (NMO) is an autoimmune condition where the CNS is affected by inflammation and demyelination. It is symptomatically similar to multiple sclerosis (MS), but there are some key differences including the fact that some treatments for MS can exacerbate NMO. Most patients with NMO have autoantibodies that target AQP4 in astrocytes and cause complement- and cell-mediated cytotoxicity. The usual treatment for NMO involves steroids and other immunosuppressants such as azathioprine and mycophenolate.

10AQP0, also known as MIP, was first identified within the lens. Its role is not only as a water channel (it has a low permeability compared to other family members, Table 1) but also to maintain the transparency and structure of the lens. Mutations in the genes for AQP0 were found to result in congenital cataracts.

11AQP5 was first found within the submandibular glands and is now known to have a role within many secretory glands including salivary, lacrimal, and sweat glands. Binding of acetylcholine to muscarinic M3 receptors is thought to induce the translocation of AQP5 vesicles to the cell surface membrane and problems with this process have been shown to be linked to conditions such as Sjögren’s syndrome.

12AQP6 is an intracellular water channel found in vesicles and its water permeability is low, as shown in Table 1. These vesicles also contain H+–ATPase and AQP6 has been found to become more active at low pH suggesting that the role of AQP6 is in acid secretion.

13AQP7, an aquaglyceroporin, is found in adipocytes and is thought to have a role in fat metabolism aiding degradation of triglycerides in fasting states. AQP7 KO mice are seen to have higher levels of fat than wild type controls and this is thought to be a therapeutic target for obesity. However, in the case of an individual with a homozygous nonfunctional AQP7 mutation, body mass index, cholesterol, and glucose levels were all normal, with only a reduced increase in glycerol levels during exercise compared to controls.

14AQP8 has been identified in the brain, small intestine, testis, and the salivary glands. Its function was disputed, but it is now known that AQP8 transports ammonia, as well as water, and that the transport of ammonia may be its primary function, maintaining acid-base equilibrium.

15AQP9, an aquaglyceroporin, is found in hepatocytes and its function is thought to be significant during periods of exercise or prolonged fasting affecting glucose production. It is found in osteoclasts and is thought to have a role in osteoporosis. It is also found in astrocytes and leukocytes. AQP9 and AQP7 are also known to mediate the uptake of arsenic compounds, which are used in some cancer treatments.

16Little is known about the remaining AQPs. AQP10, an aquaglyceroporin, is found in intestinal epithelial cells and in adipocytes. AQP11 is an intracellular aquaporin but its function remains unclear. AQP11 contains a cysteine residue instead of an alanine in its first NPA motif and in the second motif, it has a leucine instead of an arginine. It is found to be expressed in the testis, brain, kidneys, and liver. AQP11 KO mice have been found to die soon after birth due to polycystic kidney disease. This is thought to be due to AQP11 being required for correct glycosylation of polycystin-1 and -2. AQP12 is expressed in pancreatic acinar cells and in AQP12 KO models, those that develop pancreatitis develop a much more severe pathology.

17Water permeability can be assayed in various ways. Measuring volume change due to osmotic gradients is one indirect approach. Epithelial assays are based on using epithelial tissues placed on permeable supports and adding solutes to cause the fluid in a capillary tube to move. Transepithelial flux is measured via this change and fluorescent dyes can be used to evaluate permeability. Transepithelial permeability results from water flow that has occurred both cellularly and paracellularly, whereas water flux through AQPs occurs only cellularly, which is a limitation of this as an approach to deducing AQP function.

18Osmotic swelling techniques are by far the most common methods used for assaying volume changes and Xenopus oocytes are often used as they have a very low intrinsic water permeability. Osmotic gradients are used and oocytes expressing AQPs change volume when these gradients are altered. While the use of Xenopus oocytes is very common, there is substantial variability between oocyte preparations, meaning data may vary between laboratories even using the same materials.

19Microscopy techniques are also used to measure permeability via a fluorophore that is taken up by cells. Esterases within the cell produce the active fluorophore and the rate of change of fluorophore concentration can then be detected using a plate-reader or fluorescence microscope after an osmotic gradient has been applied. The limitation of this technique is that the fluorescence is relative to the dimensions of the cell monolayer where thinner cells produce a larger relative change in fluorescence than cell-lines that have a thicker monolayer. This can affect reproducibility in the same cell-line if confluence is varied between assays. It is also dependent on the amount of fluorophore that is taken up by the cells, which can sometimes be pumped out, producing variability in the data.

20Stopped-flow spectroscopy involves the use of suspensions of cells, vesicles, or proteoliposomes which are mixed with solutes to produce a change in volume. The difference in light-scattering after this volume change can then be used to calculate the volume change. Limitations of stopped-flow spectroscopy techniques include the dead time and mixing ability of the instrument used.

21Computational methods involve the use of high-resolution structures and molecular dynamics simulations, which can provide new insights into AQP structure and function at atomic resolution. However, high-quality structures are not always available and simulations can sometimes produce data that are different from experimental data. A summary of these techniques is shown in Table 2.

22Most of the molecules that are currently under investigation as AQP inhibitors target AQPs 1, 2, 3, or 4. There are many patents, clinical trials, and studies on AQP up-regulators, modulators, and inhibitors. For the purposes of this review, only AQP inhibitors are considered (Table 3).

23Several molecules have been suggested as inhibitors of various AQPs over the past few years. Of these, most are small molecules (Table 3). The similarity found between AQPs and ion channels has caused interest in ion channel modulators as possible AQP inhibitors. Arylsulfonamides such as acetazolamide are molecules that have attracted attention as potential AQP inhibitors. Anti-epileptic drugs (AEDs) have also been suggested to have an AQP modulating function. However, they have yet to be proven as definitive AQP inhibitors. A novel molecule named TGN-020 has shown great promise very recently as an inhibitor in mouse models. Micro RNA (miRNA) and small interfering RNA (siRNA) have also been used to modulate AQPs. Mercury chloride binds to a pore-lining cysteine residue found on several (but not all) AQPs and blocks the channel. Mercury and its compounds is known to be toxic due to their non-specificity which causes many off-target effects. Other heavy metal compounds (such as silver and gold compounds) have been investigated as inhibitors, but the challenge is finding a molecule with a side-effect profile that is tolerable. Currently-known inhibitors are discussed by type in the sections below.

24Tetraethylammonium (TEA) is a small molecule inhibitor that was first tested due to perceived similarities between AQPs and ion channels. Using human AQP1 expressed in Xenopus oocytes, a maximum single dose of 10 mM TEA caused a reduction in water permeability of 33%. Another study using 4 µM and 100 µM TEA showed an inhibition of 44% for Xenopus oocytes expressing AQP1, with no differences at the two concentrations; TEA also inhibited AQP2 and AQP4, with maximal inhibition of 40% and 57%, respectively, at 100 µM TEA. Further testing of TEA in Xenopus oocytes or in native AQP1-expressing erythrocytes has failed to show inhibition. TEA is thought to act by binding to a tyrosine residue located on the extracellular end of transmembrane helix 5.

25Acetazolamide is a carbonic anhydrase inhibitor used in glaucoma to reduce aqueous humor production and hence intraocular pressure. It has been shown to be a reversible inhibitor of AQP1 and AQP4 (Table 3). It has inhibitory effects on Xenopus oocytes expressing human AQP4 in a dose-dependent manner with maximal inhibition of 85% at the highest dose of 20 µM. A reduction in the water permeability of rat AQP4 (assayed in proteoliposomes) to 46% was observed at a maximum dose of 1.25 mM acetazolamide. In HEK293 cells expressing rat AQP1, there was a 39% reduction in water permeability with 100 µM acetazolamide compared to untreated rat AQP1 (using GFP fluorescence to measure swelling). However, acetazolamide appears to be unable to inhibit endogenous AQPs in human cells.

26Anti-epileptic drugs (AEDs) have also been suggested as possible AQP inhibitors. Their anti-epileptic action has been hypothesized take place through modulation of AQPs. Many AEDs such as topiramate, zonisamide, and lamotrigine are known to have a similar inhibitory effect to acetazolamide on carbonic anhydrase enzyme as well as an in silico predicted binding site on AQP4 that is similar to that hypothesized for acetazolamide. AEDs had an inhibitory effect on AQP4 in Xenopus oocytes, however, this could not be reproduced in rat thyroid epithelial cells. AEDs are thought to possibly have an inhibitory effect on AQP1, AQP4, and AQP5. However due to their unconfirmed mechanisms of action and relatively non-specific action, there is no conclusive evidence showing that AEDs are effective and safe AQP inhibitors.

27TGN-020 was shown in mouse models to significantly reduce AQP4-mediated edema following ischemia, but the molecule was administered before injury. There was an approximately 10% reduction in brain volume. Therapeutic administration must necessarily occur after a stroke, although a prophylactic treatment could be considered if the side effect profile of TGN-020 was acceptable. TGN-020 has since been tested on the same middle cerebral artery occlusion (MCAO) model and administered post-injury in mice. In a study using mouse models at a dose of 100 mg/kg, TGN-020 was administered 15 minutes post-ischemic injury and treated animals had better motor scores and less AQP4 expression around blood vessels when compared to untreated controls. The half-maximal inhibitory concentration (IC50) of TGN-020 was 3µM in Xenopus oocytes expressing human AQP4, but there is no evidence to show that TGN-020 is AQP4-specific.

28Phloretin is a small molecule that acts as a non-specific aquaglyceroporin inhibitor. It has also been shown to inhibit the urea transporter, UT-A1, found in the kidney. It has been speculated that the same mechanism underpinning urea inhibition is responsible for inhibition of the aquaglyceroporins, AQP3 and AQP9. Then 100 µM of phloretin was used to inhibit AQP9 expressed in Xenopus oocytes, resulting in an 86% inhibition. AQP3 glycerol permeability in proteoliposomes was inhibited by 500 µM phloretin, producing 83% inhibition. Phloretin had no effect on control proteoliposomes which had a Pgly of ~2.8 × 10−6 cm/s.

29A recent study identified new inhibitors of the aquaglyceroporins, AQP3 and AQP7. The compound DFP00173 was able to inhibit the glycerol permeability of human erythrocytes with an IC50 of ~0.2 µM. Compound Z433927330 reduced glycerol permeability with an IC50 of ~0.6 µM. In a Chinese hamster ovary cell-line, compound DFP00173 was able to inhibit mouse AQP3 with an IC50 of ~0.1 µM and was selective for AQP3 over AQP7 and AQP9. Compound Z433927330 was able to inhibit mouse AQP7 in the same cell-line with an IC50 of ~0.2 µM and with selectivity for AQP7 over AQP3 and AQP9; IC50s for this compound for mouse AQP3 and AQP9 were ~0.7 µM and ~1.1 µM, respectively.

30Heavy metal compounds have been used in cytotoxic treatments for many years, with the use of the platinum compound cisplatin being notable in cancer therapy. Many AQPs have been correlated with cancers, their presence influencing disease severity, increased local invasion, and the occurrence of metastasis. AQP1 overexpression has been identified in brain, breast, lung, renal, cervical, ovarian, and colorectal cancers. AQP3 overexpression has been found in skin, stomach, renal, liver, colorectal, lung, and cervical cancers. AQP3 is highly expressed in skin carcinoma cells. The uptake of glycerol through AQP3 is thought to aid the growth of these cancer cells. AQP4 overexpression is found in brain, lung, and thyroid cancers. AQP5 overexpression has been found in breast, cervical, colorectal, liver, lung, pancreatic, ovarian, and esophageal cancers. AQP7 and AQP8 overexpression are found in thyroid and cervical cancer, respectively. AQP9 overexpression has been found in brain, liver, and ovarian cancers.

31Nickel chloride has been shown to inhibit AQP3 overexpressed in human bronchial epithelium cells. Water permeability was reduced to approximately 60% in cells treated with 1 mM NiCl2 compared to non-transfected control cells. Mutational studies showed that the extracellular loop residues, Trp-128, Ser-152, and His-241, were all required for the observed inhibitory effect, but that further studies are required to confirm similar effects in other AQP3-expressing tissues such as the kidney. Copper ions also inhibit AQP3 function and attempts to reduce the toxicity of copper compounds have been addressed by using nanoparticles for delivery. Copper sulfate has been identified as an AQP3 inhibitor at 100 µM. It is believed that copper ions act by binding the same three residues on the extracellular loops as nickel ions. This inhibition mechanism is different from that of mercury ions, which bind to Cys-40 in AQP3. Copper compounds have been shown to specifically inhibit AQP3 and not AQP4, AQP5, or AQP1, while other AQPs remain to be tested. Gold-based compounds have also been used as AQP3 inhibitors and have been shown to be effective. AQP3 is found in erythrocytes, alongside AQP1, however its role is mostly for glycerol rather than both water and glycerol permeability. Erythrocytes showed a 90% decrease in glycerol permeability following treatment with 50 µM AuPhen. The binding of this gold compound is thought to be via Cys-40 and inhibition can be almost completely reversed by the addition of the reducing agent, 2-mercaptoethanol. AuPhen and other Au(III) compounds such as Auterpy were also compared with copper and platinum compounds as AQP3 inhibitors. Due to their effective inhibition of glycerol transport in AQP3, they were tested on AQP7, another aquaglyceroporin. Initial results have demonstrated that 15 µM AuPhen inhibited water and glycerol transport through AQP7: there was a reduction in water permeability (63%) as well as glycerol permeability (79%). Adipocytes overexpressing hAQP7 were used and permeability was measured using loading with 5 µM of calcein-AM and hyperosmotic shock. In silico docking studies suggest that Auphen binds AQP7 through an interaction with Met-47. Silver has also been used as a possible AQP inhibitor and is found to produce a rapid and irreversible inhibition of AQP1 in erythrocytes. It has been shown to be a much more potent inhibitor of AQP1 in erythrocytes than mercury,. Silver nitrate and silver sulfadiazine were tested as inhibitors to prevent shrinking of human erythrocytes in hyperosmotic solutions. A dose-response curve was used to calculate an IC50 of 3.9 µm and 1.24 µm and a 60% and 75% inhibition for silver nitrate and silver sulfadiazine, respectively. Gold and silver are thought to bind to sulfhydryl groups on cysteine residues of AQPs, but the complete mechanisms are not yet understood.

32An anti-AQP4 monoclonal antibody was developed as a potential treatment for NMO. “Aquaporumab” competitively binds to AQP4 in astrocytes and displaces AQP4-IgG, reducing NMO lesions in mouse models. This is yet to be tested in humans, although in vivo studies have been promising.

33A search of the European Patent Office archive in February 2019 returned 484 AQP-related patents or patent applications. These documents protect various techniques and methods such as AQP upregulation and modulation, detection methods, mRNA expression, as well as siRNA silencing techniques. Approximately 40 of these patents are for inhibitors of AQPs or NMO treatments.

34US patent 2008/0194513 A1 identifies the proliferation of blood vessels within the eyes as a factor in sight loss in several ocular conditions. Interfering RNAs were therefore used to silence AQP4 mRNA expression in order to reduce ocular neovascularization. Administration of siRNA at 1–10 nM provided over 70% inhibition of AQP4 expression in Madin-Darby canine kidney (MDCK) cells transfected with human AQP4 compared to controls. A similar patent was filed by the same inventors using similar techniques for the inhibition of AQP1 expression for ocular conditions.

35US patent 7,659,312 B2 identifies various AQP4 inhibitors to be used in cerebral edema and other water-related disorders. Twenty-one compounds are described that are similar in structure to the loop diuretics, furosemide, and bumetanide. A total of 15 compounds had inhibitory effects on AQP4 when tested in Xenopus oocytes transfected with AQP4-M23. 20 µM inhibitor compounds were used and experiments were completed twice. Aryl sulphonamide-like compounds and bi-aryl compounds were identified as inhibitors. Docking energies were also analyzed using AQP4 monomers built from electron diffraction structures; compounds with higher inhibition often had better docking energies.

36Phenylbenzamide-based compounds are patented inhibitors of AQP2 and AQP4 for the treatment of AQP-related conditions such as edema, ischemic stroke, epilepsy, and meningitis. Phenylbenzamides such as niclosamide, a compound usually used for treatment of helminth infections, is known to have an inhibitory effect on NF-kB and IKK-β. The compound IMD-0354 was used to inhibit IKK-β in myocardial ischemia models. Compound 3 has a similar structure to IMD-0354 but the two trifluromethyl groups are replaced by chloride. Compound 3 is claimed to be an inhibitor of AQP2, AQP4-M1, and AQP4-M23 with over 60% inhibition. It was at very poor inhibitor of AQP1 and AQP5. Compound 1 (IMD-0354) inhibited cerebral edema formation in a murine water toxicity model. Treatment with 0.76 mg/kg produced an 11.2% reduction, while 7.6 mg/kg showed a 15.9% reduction in edema. Following MCAO in mice, there was a 29.4% increase in survival 24 h post-injury. A subsequent patent described prodrug salts of these compounds.

37Ghrelin is a 28 amino acid peptide that is secreted by gastric mucosa cells and is a hormone that regulates hunger. It is known to also have other anti-inflammatory properties thought to be protective in neuronal injury. Traumatic brain injury (TBI) causes acute, elevated ICP and brain damage. Repeated mild brain injuries (mBI), such as concussions, can cause long-term injury to the brain and increased risk of neurodegeneration with aging. Treatments for TBI and mBI are very limited. Administration of ghrelin reduced the levels of reactive oxygen species in neurons and volume loss in mice post-injury. The administration of ghrelin at doses 1.5–1000 times native levels provided therapeutic effects lasting from 30 minutes up to 24 h. Ghrelin was also able to reduce oxidative bursts post mBI. Ghrelin has been shown to reduce levels of brain water after acute hypoxia in rats, as well as the permeability of blood vessels. It is thought to do this through reduction in TNF-α levels together with other anti-inflammatory effects on IL1, IL6, and NF-κB. In another study, levels of AQP4, serum S100B and vascular permeability were quantified to show disruption of the BBB post-TBI in mice. Treatment with ghrelin was able to reduce these levels and help prevent BBB damage post-TBI.

38A possible NMO treatment centers on a peptide corresponding to AQP4 loop C. T cells reactive to this peptide from AQP4 -/- mice produced a pathological response reminiscent of NMO when injected into AQP4 +/+ mice. T cells are found in NMO lesions and are thought to be required for the production of anti-AQP4 IgG. It was noted that immunosuppression therapy would be required before treatment takes place.

39US patent 2015/0224108 A1 presents techniques to create prodrugs and derivatives of the loop diuretics, bumetanide and furosemide, as AQP inhibitors and to aid their administration to the site of action.

40The use of phloretin as an AQP9 inhibitor was shown to reduce osteoclast levels. This inhibition would aid treatment in conditions such as osteoporosis, where excessive bone resorption takes place. AQP9 expression is higher in osteoclasts than other cells; 50 µM phloretin inhibited AQP9 expression, causing a reduction in size and number of osteoclasts but not their precursors.

41A search of the US National Library of Medicines Clinical Trials archive in February 2019 returned 61 clinical trials involving AQP-based treatments. Several of these trials examine urinary AQP2 levels and the conditions under which they are altered. Several trials also examine NMO, MS, and the therapeutic use of AQP4-IgGs. A search of the University Hospital Medical Information Network (UMIN) - Clinical Trials Registry in February 2019 returned two current clinical trials taking place using anti-AQP4 IgGs. There are currently no clinical trials taking place in the UK using AQP inhibitors or anti-AQP4 IgGs according to the UK Clinical Trials Gateway.

42Finding inhibitors for AQP water channels has been considerably more challenging than first thought. The identification of molecules that inhibit water transport through specific AQP isoforms is not a simple proposition for drug discovery on account of the high level of structural conservation within the AQP family (Table 1). The small diameter of all AQP-pores together with the chemical properties of the pore-lining amino acid side-chains mean that hydrophilic compounds are unlikely to enter and block them.

43No definitive, small molecule AQP inhibitors have been identified to date that could be used therapeutically. Heavy metal compounds are certainly effective AQP inhibitors, but their non-specificity and toxicity substantially limit their therapeutic potential. Using liposomes to administer heavy metal compounds would reduce off-target effects, but more research is required. The most promising AQP inhibitor with clinical potential to date is TGN-020, which has not yet shown any side effects in vivo, but is yet to be tested in human clinical trials. Notably, antibodies used for NMO treatment have no effect on water permeability. There is a clear need for AQP modulators, particularly in conditions such as TBI where, in the early stages, AQP4 inhibition is required to manage cytotoxic edema but, thereafter, upregulation of AQP4 would aid clearance of vasogenic edema.

44The lack of reliable in vitro phenotypic assays suitable for screening and validating the pharmacological regulation of AQP function (Table 2), means that pharmaceutical companies have been unable to meet the challenge of developing small molecules that block the AQP pore. For example, molecules discovered using Xenopus oocytes consistently fail to show efficacy in mammalian cells and vice versa. Screening programs for AQP inhibitors should therefore include multiple assays that allow more robust and reproducible readouts.

45AQPs are expressed ubiquitously and have implications in myriad human diseases. The progress of identifying AQP inhibitors has been slow and as research continues, AQPs are increasingly implicated in more diseases, highlighting the clear and urgent need for AQP modulators. More research is needed to find effective AQP inhibitors. Current screening processes are extremely variable. Approaches to standardize assays would be beneficial in identifying promising molecules for future study.